Testosterone and depression: mood benefits and their limits

Mood scores, subthreshold depression, and major depressive disorder represent different questions in testosterone research.

Group hiking on a forest trail. Photo: Chaewool Kim / Unsplash.
Written by the TrunkMD editorial team
Fact checked
Updated
  1. Updated
  2. Updated
  3. Published

Testosterone treatment may produce small improvements in mood in some men with confirmed hypogonadism. Evidence for treating a defined depressive disorder is limited and mixed, and hormone therapy is not a general substitute for depression treatment. Persistent low mood, loss of interest, or impaired functioning deserves assessment even when testosterone is low or has normalized with treatment.1234

Key points

  • A general mood-score improvement is different from remission of depression.13
  • Small trials of subthreshold depression cannot settle treatment of major depression.23
  • Hormonal and mental-health conditions can be assessed at the same time.4

Can low testosterone cause depressive symptoms?

Depressive symptoms and low testosterone can coexist, and some men with confirmed hypogonadism experience modest mood improvement with treatment. Coexistence does not establish that testosterone deficiency caused the depression, or that hormone treatment will replace depression care. Large trials and small psychiatric trials have produced different results in different populations. 12

Mood is also broader than a diagnosis. Irritability, discouragement, loss of interest, persistent sadness, and major depressive disorder are not interchangeable study endpoints. Understanding which one a trial measured is essential before turning its result into a treatment claim. Our guide to low-testosterone symptoms explains why nonspecific symptoms need context.

What did the largest recent trial find about mood?

The TRAVERSE mood analysis found small average improvements in mood and energy with testosterone among men with hypogonadism. Participants were 45-80 years old with two low fasting testosterone results, symptoms, and cardiovascular disease or elevated cardiovascular risk. About half had significant depressive symptoms on a screening scale. 1

Only 49 participants met the study's more rigorous criteria for late-onset, low-grade persistent depressive disorder. Within that small subgroup, treatment did not significantly improve the measured outcomes, and statistical power was limited. This is a useful warning against assuming that a large parent trial automatically provides a large sample for every psychiatric diagnosis. 1

The overall finding supports possible modest symptom benefit in the studied population. It does not establish testosterone as an antidepressant treatment for major depression, or as a treatment for people whose testosterone is normal.

Why do some smaller depression trials look more positive?

A 12-week randomized trial in 33 men aged at least 50 with low testosterone and subthreshold depression found greater improvement on a depression rating scale and more remissions with testosterone than placebo. The authors called for larger studies. 2

In contrast, a six-week placebo-controlled trial in men with major depressive disorder and low testosterone found no significant between-group difference in depression improvement, despite normalization of testosterone in the treatment group. 3

These studies are not interchangeable replications. They studied different depressive syndromes, used different treatment schedules, and had small samples and short follow-up. A favorable result in subthreshold symptoms cannot establish effectiveness for severe major depression. A negative short trial also cannot answer every long-term question. Each result applies to the depressive syndrome that was actually studied.

An open book rests on a wooden table in slanting light. Photo: Aaron Burden / Unsplash.

Which depression claim is actually supported?

The strongest useful statement is narrow: some trials support modest improvement in depressive symptoms in men with low testosterone, while evidence for treating a defined depressive disorder is limited and inconsistent. The table shows how the wording of the claim must change with the evidence.

Match the mood claim to the studied population
EvidenceWhat was observedWhat it does not establish
TRAVERSE symptom analysisSmall average mood and energy benefits. 1Testosterone as a general antidepressant.
33-man subthreshold-depression trialImproved depression scores and remission over 12 weeks. 2Reliable effectiveness across major depressive disorder.
Small major-depression trialNo significant benefit beyond placebo over six weeks. 3Absence of all possible mood effects in hypogonadism.
TTrials secondary mood measuresSmall favorable changes in older men with low testosterone. 5That mood improvement is universal or large.

How can a clinician separate depression from a hormone problem?

The conditions need parallel assessment rather than a forced choice. A clinician can ask about duration, loss of interest, sleep and appetite changes, concentration, functioning, and thoughts of self-harm, while reviewing the history that makes hypogonadism plausible. Depression assessment cannot be replaced by a hormone panel. 4

Likewise, a depression diagnosis does not mean relevant physical symptoms should be dismissed. Persistent sexual symptoms, a history of pituitary or testicular disease, or other compatible findings may justify endocrine investigation. Confirming a hormone disorder uses clinical context and repeated measurements, as described in how low testosterone is diagnosed.

The practical goal is to avoid delay in either direction. Waiting to see whether testosterone changes mood can leave substantial depression untreated. Assuming all physical symptoms arise from depression can overlook a separate medical condition. A plan can address both without claiming one explains everything.

Does TRT replace psychotherapy or antidepressant treatment?

The cited evidence does not support using testosterone as a general replacement for established depression treatment. NIMH describes psychotherapy, medication, and other approaches selected according to severity and individual circumstances. Treatment may require adjustment and follow-up rather than a single intervention. 4

Someone already taking psychiatric medication should discuss sexual or energy-related adverse effects with the prescribing clinician rather than abruptly stopping it to test a hormone theory. Medication changes can affect both symptoms and the ability to judge whether another treatment is helping.

If a clinician treats a genuine hormone deficiency alongside depression, the goals should remain separate: a change in sexual symptoms or a laboratory result does not automatically establish depression remission. The fatigue evidence illustrates a similar distinction between small questionnaire changes and resolution of an important daily problem.

A person in a white coat sits at a desk during a laptop video call. Photo: Vitaly Gariev / Unsplash.

What if mood worsens after starting or stopping testosterone?

A new or substantial mood change deserves clinical review. The timeline can help: when symptoms began, whether the formulation or schedule changed, whether sleep changed, and whether other medicines or substances were added or stopped. Timing suggests a possible relationship but does not by itself prove a cause.

The response should not be an unsupervised escalation intended to overcome low motivation. Mood changes can reflect a treatment issue, a separate depressive episode, disrupted sleep, or another condition. Reassessment is especially relevant when symptoms do not fit the intended treatment response.

Depression accompanied by thoughts of suicide or inability to stay safe needs immediate help. In the United States, call or text 988; call 911 for an immediate life-threatening emergency. This advice follows NIMH's depression guidance and should not wait for hormone testing. 4

How can mood benefit be evaluated without overinterpreting it?

Record a baseline that includes functioning, not only how positive or energetic someone feels on a particular day. The ability to work, engage with others, maintain routines, and experience interest can help a clinician assess meaningful change. A validated symptom questionnaire may support follow-up but does not replace a clinical diagnosis.

In the Testosterone Trials, mood changes were small and were secondary outcomes within studies designed around other primary questions. 5 That makes it reasonable to discuss possible benefit while keeping expectations measured. The relevant question is whether improvement persists and matters to the person, alongside adverse effects and the remaining burden of symptoms.

A specific claim, such as remission of major depression, requires evidence that directly measures that outcome in the relevant population. A statistically significant change in a general mood score cannot supply that evidence by itself.

Common questions

Does depression prove that testosterone is low?

No. Depression has many contributors, and its symptoms overlap with endocrine complaints. Testing depends on the full clinical context rather than mood alone.4

Can testosterone be normal while depression remains severe?

Yes. A hormone concentration does not measure depression severity. Mental-health assessment and treatment should follow the symptoms and functional impact.34

Why do online accounts sound more dramatic than trial averages?

Personal accounts select individual experiences and often include simultaneous changes in sleep, activity, medication, and expectations. Randomized trials estimate an average treatment effect and show how variable the evidence is.123

Is a depression screening score the same as a diagnosis?

No. A questionnaire identifies symptoms and can support follow-up, but a defined depressive disorder requires clinical assessment. TRAVERSE illustrates the difference: many participants had elevated symptom scores, while relatively few met its rigorous criteria for low-grade persistent depressive disorder.14

References

  1. 1.Bhasin et al. Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy. JCEM. 2024.
  2. 2.Shores et al. A randomized, double-blind, placebo-controlled study of testosterone treatment in hypogonadal older men with subthreshold depression. Journal of Clinical Psychiatry. 2009.
  3. 3.Seidman et al. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. Journal of Clinical Psychiatry. 2001.
  4. 4.NIMH. Depression.
  5. 5.Snyder et al. Effects of Testosterone Treatment in Older Men. NEJM. 2016.

This article is for general education, not medical advice, diagnosis or a treatment recommendation. A licensed clinician can interpret the evidence in the context of your symptoms, tests, medicines and fertility plans.